Someone just sent me an e-mail asking me if I knew of anyone who'd tried bioelectromagnetic therapy. Bioelectromagnetic Therapy of Fibromyalgia/Chronic Fatigue Immune Deficiency Syndrome and Magnetic Field Deficiency Syndrome/Electrical Sensitivity Trent W. Nichols, MD. Advanced Magnetic Research Institute, Hanover PA, USA. email: email@example.com http://www.ebab.eu.com/iss1_html/rtcl4/ESS1Nichols.htm Abstract Electrical Sensitivity (ES)/Magnetic Field Deficiency Syndrome (MFDS) are often seen in patients with Fibromyalgia Syndrome (FMS)/Chronic Fatigue Syndrome (CFIDS). There is much overlap between these syndromes and chronic exposure to electromagnetic fields (EMF) is common among them. Electrical Hypersensitivity (EHS) is the term the WHO prefers and recommended that research be funded to identify the relationship between EMF and EHS. EMFs are endogenous to the human body and directional signals are used in development and repair. Static Magnetic Field (SMF) therapy and DC Electromagnetic Field (DEMF) therapy have been shown in pilot studies to be beneficial in these syndromes. Possible hypothesis of their mechanism of action of DEMF are increase of cell dehydration. Introduction Electrical Sensitivity (ES)/ Magnetic Field Deficiency Syndrome (MFDS) are often seen in patients with Fibromyalgia Syndrome (FMS)/ Chronic Fatigue Immune Deficiency Syndrome (CFIDS). A history of chronic exposure to electromagnetic fields (EMF) is common. Exposure to EMFs created by computers and other electronic equipment can be obtained by taking a full history. Patients with CFIDS/ FMS will often complain of increased sensitivity to electronic equipment. Some may report inability to use computers, quartz wrist watches or other electronic appliances. Fibromylagia Syndrome (FMS) is a syndrome of a widespread musculoskeletal pain and fatigue disorder for which the cause is still unknown. From our observations in at least 20 percent of FMS patients there is sensitivity to electromagnetic fields. Devin Starlanyl, MD, has observed this phenomenon consistently in patients with FMS. “Some of us stop watches, some can’t sleep if there is a full moon, or feel wired or energized by electrical storms, and the noise of fluorescent lights can drive us up the wall.” (Starlanyl, 1996) Electromagnetic sensitivity (ES) is a progressive, disabling disease associated with exposure to electromagnetic fields, now classified as “hypersensitivity to electromagnetic fields, EMF”, created by computers and other electronic equipment. Dr William Rea, a pioneer in environmental medicine, has medically documented the existence of electromagnetic sensitivity in a double-blind study. He found that primary medical symptoms were neurological, musculoskeletal, respiratory, gastrointestinal and dermal. His conclusions were that hypersensitive persons are able to detect and identify weak fields (Rea, 1991). Gangi and Johansson reported that the central nervous system is affected with dizziness, tiredness, headache, epilepsy and slurred speech (Gangi and Johansson, ob cit). Whatever its cause, electromagnetic hypersensitivity or EHS is a real and sometimes a disabling problem for the affected persons, while the level of EMFs in their vicinity is usually no greater than is encountered in normal living environments. Their exposures are generally several orders of magnitude under the limits of internationally accepted standards. Chronic fatigue syndrome EMFs are endogenous to the human body. Embryonic L/R, Up/ Down development is dependent on endogenous electrical fields. Directional signals in development, repair and invasion are due to endogenous electrical fields (Robinson, Messerli, 2003). Endogenous electrical fields from the body originate primarily from the brain and heart, and EEG and ECG are commonplace diagnostic tests. Review of the clinical studies on Static Magnetic Field (SMF) therapy and DC Electromagnetic (DEMF) therapy in Fibromyalgia / Chronic Fatigue Immune Deficiency Syndrome/Magnetic Field Deficiency Syndrome/ Electrical Sensitivity. Six patients were selected from the practice of a Toronto internist, Dr Demarco, with most chronic, intransigent CFIDS in which other protocols were only partially successful. A study using magnetic sleep pads placed under the mattress was used for four months. Sleep pads were designed to produce a unidirectional magnetic field, to envelope the patient’s body, of about .0006T (Tesla) or 6 gauss, which would pass through the body. This was accomplished by laminating small, ceramic magnets 1 inch apart into a pad placed between the mattress and box springs of the patient’s bed. Four larger magnets were placed in a headboard producing 0.55T or 55 gauss at the centre of the head in a field perpendicular to the field produced by the bed pad. Each patient was assessed prior to the study using an interview and review of each patient’s medical record. The following five questions were used as the categories for evaluation: 1. How many hours of sleep? 2. What is the patient’s sense of well-being or optimism? 3. How many hours of work do the patient do per week? 4. What is the level of fatigue after exercise? 5. What is the patient’s comparative state of cognitive ability? At the end of four months each patient was again interviewed and assessed under the same five categories. The study administrators scored the evaluations and then compared results. Their scores matched in 25 of 30 evaluations. All patients showed improvement. Three patents improved in three of five categories, and two patients improved in four of five categories. One patient improved in all categories. There was an indication of improvement in 22 of 30 scores, or 72 percent. The authors considered the use of magnetic energy induction in the treatment of CFIDS to be efficacious in this small, pilot study (Demarco, Bonlie, 1994). A similar, double-blind, placebo-control study by Dr Lewis in Toronto in which 29 MFDS/ FMS patients were randomized to the same above magnetic pad or placebo.The study asked the question: does the induction of a 3 gauss (.003T) magnetic field affect the improvement of symptoms associated with the following five categories? 1. General health improvement 2. Energy level improvement 3. Pain decrease at pressure points 4. Sleep improvement 5. Medication required. The 20 patients in the enhanced magnetic field had an average improvement in their condition of 34.5 percent, whereas the nine placebo patients had 14.4 percent improvement. Statistical analysis of the results indicated a probability of p<.01 for active pad improvement in symptoms compared to placebo pad (Lewis, Bonlie, Miller, 1998). The DC 0.5 T (5000 gauss) electromagnetic field therapy (DEMF) is a treatment method that is hypothesized to address all the areas above except acupuncture. The DEMF is a novel treatment modality with the patient lying in the focal point between large and strong non-pulsed DC electromagnets (3,000 to 5,000 gauss). DEMF has been used on over 1,400 patients in North America under IRB-approved studies for Neurodegenerative and Orthodegenerative diseases as an experimental device, including patients with Alzheimer’s, Parkinson’s, cerebral palsy, multiple sclerosis, peripheral neuropathy, post-stroke impairment, incomplete spinal cord lesions, autism, herniated disc, osteoarthritis, fracture healing and sports injuries.